Ferring Pharmaceuticals announced that it has entered into a worldwide license agreement with Ligand Pharmaceuticals to use Ligand’s OmniAb platform to discover new human monoclonal antibodies for a range of indications. Under the agreement, Ferring will use OmniAb to accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology. Ligand's OmniAb® platforms produce highly diversified, fully human antibody repertoires optimized in vivo (in a living organism) for therapeutic efficacy and reduced immunogenicity. Ligand is eligible to receive annual platform access payments, development and regulatory milestone payments, and tiered royalties for each product developed by Ferring that incorporates an OmniAb antibody.